Irinotecan Modulates Immune Checkpoints in Neuroblastoma

Tom Lapidus, Elina Zorde-Khvalevsky, Alaa Jolani, Gal Goldstein, Amnon Peled · 2026

Read Irinotecan Modulates Immune Checkpoints in Neuroblastoma by Tom Lapidus, Elina Zorde-Khvalevsky, Alaa Jolani, Gal Goldstein, Amnon Peled (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13271423.txt.

Description

Tom Lapidus is lead author of a 2026 pilot study on how the chemotherapy drug irinotecan changes immune checkpoints on neuroblastoma cells. Neuroblastoma is the most common solid tumour outside the brain in children, and only about half of high-risk patients survive, making combined chemo-immunotherapy a central strategy.

Two neuroblastoma cell lines were exposed to low doses of irinotecan and an immune signal. The drug shifted several immune markers, including GD2, CD47, PD-L1, and MHC class I. It reduced eating of cancer cells by immune scavenger cells, but an anti-CD47 antibody reversed that. T cell killing improved after irinotecan treatment, and in mice the drug plus immune cells shrank tumours more than either alone.

Catalog record

CREATORTom Lapidus, Elina Zorde-Khvalevsky, Alaa Jolani, Gal Goldstein, Amnon Peled
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61741
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13271423

Browse the full library · About the Tower of Babel